In last trading session, Pacific Biosciences of California Inc (NASDAQ:PACB) saw 12.26 million shares changing hands with its beta currently measuring 1.98. Company’s recent per share price level of $1.69 trading at $0.04 or 2.42% at ring of the bell on the day assigns it a market valuation of $460.15M. That closing price of PACB’s stock is at a discount of -760.95% from its 52-week high price of $14.55 and is indicating a premium of 26.04% from its 52-week low price of $1.25. Taking a look at company’s average trading volume volume of 9.89 million if we extend that period to 3-months.
Pacific Biosciences of California Inc (NASDAQ:PACB) trade information
Upright in the green during last session for gaining 2.42%, in the last five days PACB remained trading in the green while hitting it’s week-highest on Wednesday, 05/01/24 when the stock touched $1.69 price level, adding 7.65% to its value on the day. Pacific Biosciences of California Inc’s shares saw a change of -82.77% in year-to-date performance and have moved 24.26% in past 5-day. Pacific Biosciences of California Inc (NASDAQ:PACB) showed a performance of -50.44% in past 30-days.
Pacific Biosciences of California Inc (PACB) estimates and forecasts
Statistics highlight that Pacific Biosciences of California Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -76.23% of value to its shares in past 6 months, showing an annual growth rate of 9.91% while that of industry is 14.30. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 25.00% in the current quarter and calculating 10.70% increase in the next quarter. This year revenue growth is estimated to rise 2.10% from the last financial year’s standing.
11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $42.96 million for the same. And 10 analysts are in estimates of company making revenue of $46.63 million in the next quarter that will end on Jun 2024. Company posted $34.38 million and -$ of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -9.76% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 15.59% while estimates for its earnings growth in next 5 years are of -1.00%.
PACB Dividends
Pacific Biosciences of California Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
